Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03245320 · ClinicalTrials.gov registry record
Clinical Evaluation of the TITAN™ Total Shoulder System
A clinical trial, sponsored by Smith & Nephew.
- Terminated
- Registry status
- 50
- Enrollment target
NCT03245320: Clinical Trial study, sponsored by Smith & Nephew.
NCT03245320 is a clinical trial that was terminated before completion, run by Smith & Nephew. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03245320 was terminated before completion, sponsored by Smith & Nephew.
- TERMINATED
- Registry status
- 50 participants
- Enrollment target
Study Summary
A post market, non-randomized, multi-center, open-label,clinical study using survivorship to study the safety and efficacy of the Integra® TITAN™ Total Shoulder System 1.0 (TAS) when used for total shoulder arthroplasty.
Primary Outcome
Implant survivorship is defined as absence of device removal or revision of one or more of the implant component(s).
Interventions
- DEVICE Integra TITAN™ Total Shoulder Generation 1.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2022-06-23 |
Why NCT03245320 stopped before completion
NCT03245320 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Integra TITAN™ Total Shoulder Generation 1.0 is the first listed.
NCT03245320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03245320 about?
NCT03245320 is a clinical study titled "Clinical Evaluation of the TITAN™ Total Shoulder System". A post market, non-randomized, multi-center, open-label,clinical study using survivorship to study the safety and efficacy of the Integra® TITAN™ Total Shoulder System 1.0 (TAS) when used for total shoulder arthroplasty.
What is the current status of trial NCT03245320?
This trial is currently terminated. The enrollment target is 50 participants. The study started on 2017-03-20. Estimated completion is 2022-06-23.
What interventions are being tested in trial NCT03245320?
The interventions under investigation include: Integra TITAN™ Total Shoulder Generation 1.0 (DEVICE).
Who is sponsoring clinical trial NCT03245320?
This trial is sponsored by Smith & Nephew, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI